生物制药公司Immunovant, Inc. (IMVT) 今日盘中股价大幅上涨31.76%，表现异常强劲。
消息面上，公司今日发布了截至2026年3月31日的第四季度及整个财年的财务业绩，并同步更新了业务进展。然而，推动股价飙升的核心动力来自于其核心在研药物IMVT-1402的积极临床试验数据。
数据显示，用于治疗难治性类风湿关节炎的IMVT-1402在临床试验中取得了显著效果。在接受600毫克剂量治疗16周后，近73%的患者在关节压痛和肿胀方面实现了至少20%的改善，超过一半的患者实现了50%的改善。这一积极的临床突破完全盖过了公司财报中公布的季度亏损，极大地提振了市场对公司未来前景的信心，并促使投资者积极买入。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.